spHolder

Nurturing the next scientific breakthroughs

Back to news

15 August 2024

Nurturing the next scientific breakthroughs

The rapidly growing life sciences sector has become a new focal point for investors, industry, and government since the pandemic.. However, most research and development is still conducted in closed labs on university campuses. Australia’s first commercialised life sciences precinct is gearing up to change that – and its investment and development manager, Kurraba Group, has big ambitions for what comes next.
 

This feature in this month’s Forbes Australia magazine discusses Kurraba Group’s ambitions  to be Australia’s first commercialised life sciences precinct and how the plan is coming to fruition with the $490m planned development located at 100 Botany Road, Waterloo.

 

Since the COVID-19 pandemic accelerated the development of the life sciences sector, many have looked to this growing industry for everything from cancer cures and infection antidotes to climate change solutions and the future of agriculture.
 

Australia has traditionally punched well above its weight on life-changing breakthroughs, with the HPV vaccine, the cochlear implant, the pacemaker, the black box flight recorder and the medical use of penicillin among our credits.
 

In recent years, however, Australia has been losing some of our life sciences talent to global counterparts, with innovators increasingly attracted to funding, research and collaboration opportunities found offshore.





Nick Smith CEO says, 
 

“We think of it as the fourth industrial revolution. The formation of the life sciences thematic behind Kurraba came from our drive to look at an alternative asset class interested in the longevity of people and the benefit of humans.’
 

“It’s much more about the science, the R&D and the technology coming through. It’s a property class with a cause.”

Download Pdf